Vivos (RDGL) Other Non-Current Assets (2010 - 2025)

Vivos (RDGL) reported Other Non-Current Assets of $3000.0 for Q4 2025, up 348.43% sequentially from $669.0 in Q3 2018.

Vivos (RDGL) Other Non-Current Assets (2010 - 2025) Analysis & Trends

Vivos (RDGL) has 10 years of Other Non-Current Assets data on file, last reported at $3000.0 in Q4 2025.

For the quarter ending Q4 2025, Other Non-Current Assets changed N/A year-over-year to $3000.0; the trailing twelve-month figure through Dec 2025 stood at $3000.0 (changed N/A YoY), and the FY2025 full-year result was $3000.0, changed N/A from the prior year.
Other Non-Current Assets grew to $3000.0 in Q4 2025, from $669.0 in the prior quarter.
In the past five years, Other Non-Current Assets ranged from a high of $3000.0 in Q4 2025 to a low of $3000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn	-
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	3.17 Bn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn	4.15 Bn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn	2.05 Bn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn	738.90 Mn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn	285.90 Mn
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn	2.25 Bn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-	164.00 Mn
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn	828.89 Mn
10	Vivos	27.16 Mn	25.60 Mn	-3,105.00	3,000.00

Download Data